Jason Wittes
Stock Analyst at Roth Capital
(2.65)
# 1,812
Out of 5,182 analysts
58
Total ratings
49.02%
Success rate
4.01%
Average return
Main Sectors:
Stocks Rated by Jason Wittes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRY ARS Pharmaceuticals | Initiates: Buy | $40 | $8.83 | +353.00% | 1 | Sep 4, 2025 | |
| SYK Stryker | Maintains: Buy | $405 → $456 | $290.88 | +56.77% | 11 | May 2, 2025 | |
| FBIO Fortress Biotech | Reiterates: Buy | $15 → $16 | $2.38 | +572.27% | 3 | Mar 11, 2025 | |
| OFIX Orthofix Medical | Reiterates: Buy | $22 | $12.00 | +83.33% | 5 | Feb 26, 2025 | |
| IRMD IRADIMED CORPORATION | Reiterates: Buy | $60 → $72 | $84.92 | -15.21% | 3 | Feb 14, 2025 | |
| TLSI TriSalus Life Sciences | Reiterates: Buy | $11 | $4.44 | +147.75% | 2 | Jan 24, 2025 | |
| GMED Globus Medical | Maintains: Buy | $100 → $115 | $90.60 | +26.93% | 4 | Dec 17, 2024 | |
| DERM Journey Medical | Reinstates: Buy | $11 | $5.12 | +114.84% | 1 | Jun 28, 2024 | |
| CRDL Cardiol Therapeutics | Initiates: Buy | $10 | $1.33 | +651.88% | 1 | Jun 26, 2024 | |
| LMAT LeMaitre Vascular | Reinstates: Buy | $100 | $111.53 | -10.34% | 1 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.90 | +163.16% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $0.46 | +1,856.10% | 2 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $23.34 | +221.34% | 2 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $10.33 | +112.97% | 3 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $120 | $82.67 | +45.16% | 7 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $206 | $178.21 | +15.59% | 1 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $145 | $192.09 | -24.51% | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7.5 | $16.42 | -54.32% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $16.93 | +1,081.33% | 3 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $35.71 | -27.18% | 1 | Feb 22, 2017 |
ARS Pharmaceuticals
Sep 4, 2025
Initiates: Buy
Price Target: $40
Current: $8.83
Upside: +353.00%
Stryker
May 2, 2025
Maintains: Buy
Price Target: $405 → $456
Current: $290.88
Upside: +56.77%
Fortress Biotech
Mar 11, 2025
Reiterates: Buy
Price Target: $15 → $16
Current: $2.38
Upside: +572.27%
Orthofix Medical
Feb 26, 2025
Reiterates: Buy
Price Target: $22
Current: $12.00
Upside: +83.33%
IRADIMED CORPORATION
Feb 14, 2025
Reiterates: Buy
Price Target: $60 → $72
Current: $84.92
Upside: -15.21%
TriSalus Life Sciences
Jan 24, 2025
Reiterates: Buy
Price Target: $11
Current: $4.44
Upside: +147.75%
Globus Medical
Dec 17, 2024
Maintains: Buy
Price Target: $100 → $115
Current: $90.60
Upside: +26.93%
Journey Medical
Jun 28, 2024
Reinstates: Buy
Price Target: $11
Current: $5.12
Upside: +114.84%
Cardiol Therapeutics
Jun 26, 2024
Initiates: Buy
Price Target: $10
Current: $1.33
Upside: +651.88%
LeMaitre Vascular
May 31, 2024
Reinstates: Buy
Price Target: $100
Current: $111.53
Upside: -10.34%
Mar 5, 2024
Reiterates: Buy
Price Target: $5
Current: $1.90
Upside: +163.16%
Feb 13, 2024
Initiates: Buy
Price Target: $9
Current: $0.46
Upside: +1,856.10%
Oct 20, 2023
Initiates: Buy
Price Target: $75
Current: $23.34
Upside: +221.34%
Oct 20, 2023
Initiates: Buy
Price Target: $22
Current: $10.33
Upside: +112.97%
Oct 20, 2023
Initiates: Neutral
Price Target: $120
Current: $82.67
Upside: +45.16%
Sep 14, 2022
Initiates: Buy
Price Target: $206
Current: $178.21
Upside: +15.59%
Jun 27, 2022
Reinstates: Buy
Price Target: $145
Current: $192.09
Upside: -24.51%
Mar 3, 2022
Initiates: Buy
Price Target: $7.5
Current: $16.42
Upside: -54.32%
Feb 8, 2022
Initiates: Buy
Price Target: $200
Current: $16.93
Upside: +1,081.33%
Feb 22, 2017
Initiates: Buy
Price Target: $26
Current: $35.71
Upside: -27.18%